Multiple Sclerosis Clinical Trial
Official title:
Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment and Evaluation of Endocannabinoid System Activity
Pain represents one of the most common symptoms of Multiple Sclerosis (MS) that can
seriously affect patient health-related quality of life.
Central neuropathic pain, the main form of pain in MS patients, represents a significant
clinical problem, in consideration of its poorly responsiveness to available therapies.
Direct Current Stimulation (tDCS) is a non-invasive, well-tolerated procedure with an high
and well documented neuromodulation activity at Central Nervous System (CNS) level. First
evidences obtained by animal, neurophysiological and clinical studies suggested its
potential efficacy in neuropathic pain treatment.
In particular spinal DCS (sDCS) has been proven to modulate Nociceptive Withdrawal Reflex
(NWR), an objective and sensitive tool to explore pain processing at the Spinal Level and
recommended by European Federation of Neurological Society (EFNS) to evaluate the analgesic
effect of treatments. In this order of view the investigators' objective is to investigate
sDCS efficacy in MS neurophatic pain treatment applying validated clinical scales,
neurophysiological acquisitions and specific biological marker dosages.
The investigators plan to recruit, at the IRCCS Neurological National Institute C. Mondino,
60 consecutive patients with definite Multiple Sclerosis (MS) according to 2005 McDonald
criteria in a follow-up procedure that includes a general and neurological evaluation scored
according to the Expanded Disability Status Scale of Kurtzke and its functional systems.
Relapsing-remitting (RR), secondary-progressive (SP) and primary-progressive (PP) MS
patients, affecting by neuropathic or nociceptive chronic pain conditions in accord to 1994
International Association for the Study of Pain (IASP)classification, will be recruited.
Patients complaining any form of headache will be excluded by the study. The investigators
will excluded also patients with cognitive impairment (Minimental State Examination - MMSE-
<= 21) and psychiatry diseases, in particular depression (Back Depression Inventory Scale -
BDI - >15).
Characteristic and intensity of pain symptoms will be collected respectively with validated
Italian version of Neuropathic Pain Symptoms Inventory Scale (NPSI) and Numerical Rating
Scale (NRS). Spasticity of lower legs, if present, will be clinical assessed with Ashworth
Scale and Neurophysiologically evaluated with H/M ratio and Vibratory Inhibition of
H-Reflex.
Health-Related Quality of Life (HRQoL) will be assessed by means of the Medical Outcome
36-item Short Form Health Survey (SF-36) whereas the presence and severity of fatigue will
be assessed by means of the Fatigue Severity Scale (FSS).
RR patients will be evaluated in stationary phase of the disease that is at least two months
after the last clinical relapse and at least one month after the end of a steroidal
treatment.
Patients will be consecutive enrolled in the study and randomly assigned to two group: 1.
Sham and 2. Anodal Spinal Direct Current Stimulation Treatment, in a double-blind, placebo
controlled study design.
Before enrollment, the study protocol will be explained to each subject, and informed
written consent will be obtained.
The investigators will proceed as follow:
1. Time of enrollment - T0 First Day
- Complete clinical evaluation with administration of MMSE and BDI for exclusion
criteria
- Randomized assignment to Anodal or Sham treatment group
- Administration of NPSI, SF-36, HRQoL e FSS
- Evaluation of Somatosensory Evoked Potential by Posterior Tibial and Medial Nerve
stimulation to investigate the somatosensory pathway involvement.
- Clinical and Neurophysiological evaluation of Spasticity (if present): Ashworth
Scale and H/M ratio and HReflex Vibratory Inhibition.
- Collection of blood sample to evaluate activity of Fatty Acid Amide Hydrolase
(FAAH) in platelets.
Second Day
- First Anodal or Sham Direct Current Stimulation Treatment Session (sDCS)
- Neurophysiological acquisition of Nociceptive Withdrawal Reflex (NWR) and NWR
Temporal Summation (see 'Neurophysiological Acquisition' Session for details)
before and after 30 and 60 minutes the first sDCS treatment
2. sDCS Treatment After evaluation at T0 patients will undergo 10 daily sDCS treatment, 5
days a week (see sDCS treatment session for details).
3. Evaluation after 10 days of treatment - T1
- Administration of NPSI, SF-36, HRQoL e FESS
- Clinical and Neurophysiological evaluation of Spasticity (if present): Ashworth
Scale and H/M ratio and HReflex Vibratory Inhibition.
- Collection of blood sample to evaluate activity of Fatty Acid Amide Hydrolase
(FAAH) in platelets.
- Neurophysiological acquisition of Nociceptive Withdrawal Reflex (NWR) and NWR
Temporal Summation
4. Evaluation after 1 month from the end of treatment - T2
- Administration of NPSI, SF-36, HRQoL e FESS
- Clinical and Neurophysiological evaluation of Spasticity (if present): Ashworth
Scale and H/M ratio and HReflex Vibratory Inhibition.
- Collection of blood sample to evaluate activity of Fatty Acid Amide Hydrolase
(FAAH) in platelets.
- Neurophysiological acquisition of Nociceptive Withdrawal Reflex (NWR) and NWR
Temporal Summation
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |